
By: Oded Ben-Joseph, PhD, MBA
Outcome Capital
We founded our company, Outcome Capital, with the aim of offering advisory, transactional and operational advice to growing companies within the life sciences, health care services, and technology space. We are a multi-disciplinary team of former CEOs, company founders, institutional investors and bankers, MBAs, and scientists with a wide range of operational, strategic and private equity experience and expertise spanning a variety of backgrounds. We are passionate about supporting the development of companies and their management teams, helping them to build successful businesses and to realize the greatest value of their efforts in their deals and exits. And after 18 years of business, it is our great desire to pass on to a new generation of business leaders the wealth of knowledge we have gained through our many years of advising and working with companies to carve out and follow their best path to success.
We intend to use this blog to convey our thoughts on a variety of business and management topics. These will include practical advice to CEOs and business development professionals on transactional pitfalls and strategies for success. We will discuss specific case studies arising from our experiences in advising growing companies on their development efforts, corporate transactions, and exit strategies. We will also share our thoughts on specific markets and evolving business opportunities, as well as on recent industry events and what executives can learn from them.
We hope you find our posts over the coming weeks entertaining and enlightening.
This article examines the quiet but profound reset underway in U.S. biotech, triggered by a rare combination of forces: delayed or reduced federal funding, large pharma cutting mid-stage partnerships, and venture capital pulling back as exits evaporate. Based on insights from Dr. Stanislav Glezer, it reveals a market splitting in two — with capital chasing late-stage and very early assets while Phase 1–2 companies are stranded in the middle. The piece also exposes how government uncertainty, shrinking NIH support, and overlooked patient-behavior realities are forcing founders to rethink their entire company lifecycle. In today’s environment, survival requires new strategies, new geographies, and a deeper understanding of human factors that no protocol can fix.
Read More
Outcome Capital Life Science Market Pulse October 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?